Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chiglitazar for cognitive function in type 2 diabetes mellitus with mild cognitive impairment
ChiCTR2600135134Phase 4Recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in type 2 diabetes mellitus (T2DM) and Mild Cognitive Impairment (MCI) comparing Placebo group with Chiglitazar 48 mg group (2 arms). Primary endpoint: Mini-Mental State Examination score. Started Mar 2026; status: recruiting.
02
Drugs
chiglitazar
03
Conditions
type 2 diabetes mellitus (T2DM)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on ChiCTR2600135134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135134.